Skip to content
Screener

uniQure QURE Business Segments — Allocated Share Based Compensation Expense

Similar metrics at other companies

Edgewise Therapeutics, Inc. logo
EWTXSingle Reportable — Allocated Share Based Compensation Expense
$8.72M-3.8%
Vuzix logo
VUZISingle Reportable — Allocated Share Based Compensation Expense
$4.11M-24.0%
Research Solutions logo
RSSSSingle Reportable — Allocated Share Based Compensation Expense
$248.61K-58.2%
Ocular Therapeutix logo
OCULSingle Reportable — Allocated Share Based Compensation Expense
$15.58M+49.0%
Protagonist Therapeutics logo
PTGXSingle Reportable — Allocated Share Based Compensation Expense
$14.04M+28.6%
Farmland Partners logo
FPISingle Reportable — Allocated Share Based Compensation Expense
-$468K+9.8%

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Cash & equivalents$413.0M+62.8%
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Segment operating loss(35,637)(32,326)(74,848)(66,636)
Reconciliation
Depreciation and amortization expense(4,907)(3,630)(7,863)(8,157)
Share-based compensation expense(5,016)(5,084)(10,106)(9,494)
Fair value (loss) / gain - contingent consideration(1,256)(2,254)82(3,470)
Fair value loss - Liability related to pre-funded warrants(15,970)(12,201)
Foreign currency (losses) / gains, net(1,730)18,638(4,024)25,810
Interest income5,0513,52410,2807,651

Item 1.Financial Statements

FAQ

What is uniQure's business segments — allocated share based compensation expense?
uniQure (QURE) reported business segments — allocated share based compensation expense of $5.02M in Q2 2026.
How has uniQure's business segments — allocated share based compensation expense changed year-over-year?
uniQure's business segments — allocated share based compensation expense decreased by 1.3% year-over-year, from $5.08M to $5.02M.
What is the long-term trend for uniQure's business segments — allocated share based compensation expense?
Over 3 years (2022 to 2025), uniQure's business segments — allocated share based compensation expense has grown at a -19.7% compound annual growth rate (CAGR), from -$34.2M to $17.68M.
What does business segments — allocated share based compensation expense mean?
Reflects the non-cash expense recognized for equity-based awards granted to employees and directors associated with the primary business segment. This metric is essential for evaluating the total cost of talent and the impact of equity dilution on financial performance.

Ask your AI about uniQure's business segments — allocated share based compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude